Research & Literature

Magnetic resonance parkinsonism index in progressive supranuclear palsy and vascular parkinsonism.

Mostile G, Nicoletti A, Cicero CE, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2016; (37(4)):591-5 doi:10.1007/s10072-016-2489-x.

Clinical Approach to Progressive Supranuclear Palsy.

Ling H

Journal of movement disorders 2016; (9(1)):3-13 doi:10.14802/jmd.15060.

Diagnostic accuracy of Magnetic Resonance Parkinsonism Index in differentiating progressive supranuclear palsy from Parkinson's disease and controls in Indian patients.

Sankhla CS, Patil KB, Sawant N, Gupta S

Neurology India 2016; (64(2)):239-45 doi:10.4103/0028-3886.177611.

Highly specific radiographic marker predates clinical diagnosis in progressive supranuclear palsy.

Owens E, Krecke K, Ahlskog JE, et al.

Parkinsonism & related disorders 2016; (28()):107-11.

Imaging in Parkinson's disease.

Pagano G, Niccolini F, Politis M

Clinical medicine (London, England) 2016; (16(4)):371-5 doi:10.7861/clinmedicine.16-4-371.

Manual MRI morphometry in Parkinsonian syndromes.

Möller L, Kassubek J, Südmeyer M, et al.

Movement disorders : official journal of the Movement Disorder Society 2017; (32(5)):778-782 doi:10.1002/mds.26921.

Nonmotor Features in Atypical Parkinsonism.

Bhatia KP, Stamelou M

International review of neurobiology 2017; (134()):1285-1301 doi:10.1016/bs.irn.2017.06.001.

Botulinum toxin in parkinsonism: The when, how, and which for botulinum toxin injections.

Cardoso F

Toxicon : official journal of the International Society on Toxinology 2018; (147()):107-110 doi:10.1016/j.toxicon.2017.08.018.

A case of spinal anesthesia in a patient with progressive supranuclear palsy.

Tonan M, Egi M, Furushima N, Mizobuchi S

JA clinical reports 2018; (4(1)):12 doi:10.1186/s40981-018-0149-2.

MRI Planimetry and Magnetic Resonance Parkinsonism Index in the Differential Diagnosis of Patients with Parkinsonism.

Constantinides VC, Paraskevas GP, Velonakis G, et al.

AJNR. American journal of neuroradiology 2018; (39(6)):1047-1051 doi:10.3174/ajnr.A5618.

The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism.

Mueller C, Hussl A, Krismer F, et al.

Parkinsonism & related disorders 2018; (54()):90-94 doi:10.1016/j.parkreldis.2018.04.005.

Tau in neurodegenerative disease.

Gao YL, Wang N, Sun FR, et al.

Annals of translational medicine 2018; (6(10)):175 doi:10.21037/atm.2018.04.23.

A new MR imaging index for differentiation of progressive supranuclear palsy-parkinsonism from Parkinson's disease.

Quattrone A, Morelli M, Nigro S, et al.

Parkinsonism & related disorders 2018; (54()):3-8 doi:10.1016/j.parkreldis.2018.07.016.

Comparative cognitive and neuropsychiatric profiles between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.

Santangelo G, Cuoco S, Pellecchia MT, et al.

Journal of neurology 2018; (265(11)):2602-2613 doi:10.1007/s00415-018-9038-x.

Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.

Brittain C, McCarthy A, Irizarry MC, et al.

Parkinsonism & related disorders 2019; (60()):138-145 doi:10.1016/j.parkreldis.2018.08.025.

Prevalence of pain in atypical parkinsonism: a systematic review and meta-analysis.

Rana AQ, Qureshi AR, Siddiqui O, et al.

Journal of neurology 2019; (266(9)):2093-2102 doi:10.1007/s00415-018-9049-7.

Sensitivity and Specificity of Diagnostic Criteria for Progressive Supranuclear Palsy.

Ali F, Martin PR, Botha H, et al.

Movement disorders : official journal of the Movement Disorder Society 2019; (34(8)):1144-1153 doi:10.1002/mds.27619.

Pyramidal system involvement in progressive supranuclear palsy - a clinicopathological correlation.

Stejskalova Z, Rohan Z, Rusina R, et al.

BMC neurology 2019; (19(1)):42 doi:10.1186/s12883-019-1270-1.

Emerging drugs for progressive supranuclear palsy.

Giagkou N, Stamelou M

Expert opinion on emerging drugs 2019; (24(2)):83-92 doi:10.1080/14728214.2019.1609450.

Progression of two Progressive Supranuclear Palsy phenotypes with comparable initial disability.

Shoeibi A, Litvan I, Tolosa E, et al.

Parkinsonism & related disorders 2019; (66()):87-93 doi:10.1016/j.parkreldis.2019.07.010.

Progressive supranuclear palsy as differential diagnosis of Parkinson's disease in the elderly.

Fernández-Ferreira R, García-Santos RA, Rodríguez-Violante M, et al.

Revista espanola de geriatria y gerontologia 2019; (54(5)):251-256 doi:10.1016/j.regg.2019.04.002.

Increased Signal in the Superior Cerebellar Peduncle of Patients with Progressive Supranuclear Palsy.

Kataoka H, Nishimori Y, Kiriyama T, et al.

Journal of movement disorders 2019; (12(3)):166-171 doi:10.14802/jmd.19002.

Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy.

Sakae N, Josephs KA, Litvan I, et al.

Movement disorders : official journal of the Movement Disorder Society 2019; (34(11)):1655-1662 doi:10.1002/mds.27816.

Chameleons and mimics: Progressive supranuclear palsy and corticobasal degeneration.

Mimuro M, Yoshida M

Neuropathology : official journal of the Japanese Society of Neuropathology 2020; (40(1)):57-67 doi:10.1111/neup.12590.

Midbrain morphology in idiopathic normal pressure hydrocephalus: A progressive supranuclear palsy mimic.

Constantinides VC, Paraskevas GP, Velonakis G, et al.

Acta neurologica Scandinavica 2020; (141(4)):328-334 doi:10.1111/ane.13205.

Brain volume and flortaucipir analysis of progressive supranuclear palsy clinical variants.

Whitwell JL, Tosakulwong N, Botha H, et al.

NeuroImage. Clinical 2020; (25()):102152 doi:10.1016/j.nicl.2019.102152.

The Progressive Supranuclear Palsy Clinical Deficits Scale.

Piot I, Schweyer K, Respondek G, et al.

Movement disorders : official journal of the Movement Disorder Society 2020; (35(4)):650-661 doi:10.1002/mds.27964.

Magnetic Resonance Parkinsonism Index for evaluating disease progression rate in progressive supranuclear palsy: A longitudinal 2-year study.

Quattrone A, Morelli M, Quattrone A, et al.

Parkinsonism & related disorders 2020; (72()):1-6 doi:10.1016/j.parkreldis.2020.01.019.

Structure of NFT: Biochemical Approach.

Hasegawa M

Advances in experimental medicine and biology 2019; (1184()):23-34 doi:10.1007/978-981-32-9358-8_2.

Fibrillation and molecular characteristics are coherent with clinical and pathological features of 4-repeat tauopathy caused by MAPT variant G273R.

Sandberg A, Ling H, Gearing M, et al.

Neurobiology of disease 2020; (146()):105079 doi:10.1016/j.nbd.2020.105079.

Two Patients with Niemann Pick Disease Type C Diagnosed in the Seventh Decade of Life.

Wu M, Ceponiene R, Bayram E, Litvan I

Movement disorders clinical practice 2020; (7(8)):961-964 doi:10.1002/mdc3.13085.

Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism.

Heim B, Mangesius S, Krismer F, et al.

Parkinsonism & related disorders 2021; (82()):87-91 doi:10.1016/j.parkreldis.2020.11.019.

Disease course and treatment patterns in progressive supranuclear palsy: A real-world study.

Morgan JC, Ye X, Mellor JA, et al.

Journal of the neurological sciences 2021; (421()):117293 doi:10.1016/j.jns.2020.117293.

Molecular Processing of Tau Protein in Progressive Supranuclear Palsy: Neuronal and Glial Degeneration.

Martínez-Maldonado A, Ontiveros-Torres MÁ, Harrington CR, et al.

Journal of Alzheimer's disease : JAD 2021; (79(4)):1517-1531 doi:10.3233/JAD-201139.

Association of PSP phenotypes with survival: A brain-bank study.

Guasp M, Molina-Porcel L, Painous C, et al.

Parkinsonism & related disorders 2021; (84()):77-81 doi:10.1016/j.parkreldis.2021.01.015.

The Role of Frontal Assessment Battery and Frontal Lobe Single-Photon Emission Computed Tomography in the Differential Diagnosis of Progressive Supranuclear Palsy Variants and Corticobasal Syndrome-A Pilot Study.

Alster P, Migda B, Madetko N, et al.

Frontiers in neurology 2021; (12()):630153 doi:10.3389/fneur.2021.630153.

Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy.

Miki Y, Tsushima E, Foti SC, et al.

Brain : a journal of neurology 2021; (144(4)):1138-1151 doi:10.1093/brain/awab017.

Subtypes of PSP and Prognosis: A Retrospective Analysis.

Mahale RR, Krishnan S, Divya KP, et al.

Annals of Indian Academy of Neurology 2021; (24(1)):56-62 doi:10.4103/aian.AIAN_611_20.

Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis.

Heim B, Krismer F, Seppi K

Journal of neural transmission (Vienna, Austria : 1996) 2021; (128(10)):1497-1505 doi:10.1007/s00702-021-02362-8.

Clinical Features of Patients With Progressive Supranuclear Palsy in an US Insurance Claims Database.

Viscidi E, Litvan I, Dam T, et al.

Frontiers in neurology 2021; (12()):571800 doi:10.3389/fneur.2021.571800.

Methods and utility of quantitative brainstem measurements in progressive supranuclear palsy versus Parkinson's disease in a routine clinical setting.

Cooperrider J, Bluett B, Jones SE

Clinical parkinsonism & related disorders 2020; (3()):100033 doi:10.1016/j.prdoa.2020.100033.

Novel Therapies for Parkinsonian Syndromes-Recent Progress and Future Perspectives.

Przewodowska D, Marzec W, Madetko N

Frontiers in molecular neuroscience 2021; (14()):720220 doi:10.3389/fnmol.2021.720220.

iPS Cell-Based Model for MAPT Haplotype as a Risk Factor for Human Tauopathies Identifies No Major Differences in TAU Expression.

Strauß T, Marvian-Tayaranian A, Sadikoglou E, et al.

Frontiers in cell and developmental biology 2021; (9()):726866 doi:10.3389/fcell.2021.726866.

"Parkinson's disease" on the way to progressive supranuclear palsy: a review on PSP-parkinsonism.

Necpál J, Borsek M, Jeleňová B

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2021; (42(12)):4927-4936 doi:10.1007/s10072-021-05601-8.

Human Tau Isoforms and Proteolysis for Production of Toxic Tau Fragments in Neurodegeneration.

Boyarko B, Hook V

Frontiers in neuroscience 2021; (15()):702788 doi:10.3389/fnins.2021.702788.

An Unusual Presentation of Progressive Supranuclear Palsy.

Dec-Cwiek M, Boczarska-Jedynak M, Pera J

Neurology India 2021; (69(6)):1789-1793 doi:10.4103/0028-3886.333499.

[Autonomic Dysfunction in Tauopathies].

Koga S, Aiba I

Brain and nerve = Shinkei kenkyu no shinpo 2022; (74(3)):257-262 doi:10.11477/mf.1416202021.

Progressive supranuclear palsy with predominant frontal presentation exhibiting progressive nonfluent aphasia due to crossed aphasia.

Ono Y, Higashida K, Yoshikura N, et al.

Neuropathology : official journal of the Japanese Society of Neuropathology 2022; (42(3)):232-238 doi:10.1111/neup.12805.

Do Patients with Progressive Supranuclear Palsy Have Episodic Memory Impairment? A Systematic Review.

Macedo AC, Mariano LI, Martins MI, et al.

Movement disorders clinical practice 2022; (9(4)):436-445 doi:10.1002/mdc3.13435.

Diffusion tractography of superior cerebellar peduncle and dentatorubrothalamic tracts in two autopsy confirmed progressive supranuclear palsy variants: Richardson syndrome and the speech-language variant.

Gatto RG, Martin PR, Ali F, et al.

NeuroImage. Clinical 2022; (35()):103030 doi:10.1016/j.nicl.2022.103030.

[Atypical Parkinson's syndrome in old age].

Iglseder B, Lange R

Zeitschrift fur Gerontologie und Geriatrie 2022; (55(5)):421-430 doi:10.1007/s00391-022-02077-9.

Autopallidotomy: From Colloquial Term to Scientific Theory.

McCarter SJ, Savica R

Journal of Parkinson's disease 2022; (12(7)):2009-2013 doi:10.3233/JPD-223491.

Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy.

Debnath M, Dey S, Sreenivas N, et al.

Annals of neurosciences 2022; (29(2-3)):177-188 doi:10.1177/09727531221089396.

PDQ-8: A Simplified and Effective Tool Measuring Life Quality in Progressive Supranuclear Palsy.

Li XY, Chen MJ, Liang XN, et al.

Journal of Parkinson's disease 2023; (13(1)):83-91 doi:10.3233/JPD-223553.

Differences in Striatal Metabolism in [18F]FDG PET in Parkinson's Disease and Atypical Parkinsonism.

Seiffert AP, Gómez-Grande A, Alonso-Gómez L, et al.

Diagnostics (Basel, Switzerland) 2022; (13(1)) doi:10.3390/diagnostics13010006.

Dopamine transporter SPECT imaging in Parkinson's disease and atypical Parkinsonism: a study of 137 patients.

Constantinides VC, Souvatzoglou M, Paraskevas GP, et al.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology 2023; (44(5)):1613-1623 doi:10.1007/s10072-023-06628-9.

The Role of Tau Proteoforms in Health and Disease.

Waheed Z, Choudhary J, Jatala FH, et al.

Molecular neurobiology 2023; (60(9)):5155-5166 doi:10.1007/s12035-023-03387-8.

Diagnostic accuracy of cerebral [18F]FDG PET in atypical parkinsonism.

Houssein NJ, Henriksen AC, Hejl AM, Marner L

EJNMMI research 2023; (13(1)):74 doi:10.1186/s13550-023-01025-x.

Clinical features of progressive supranuclear palsy.

Wen Y, Yang Q, Jiao B, et al.

Frontiers in aging neuroscience 2023; (15()):1229491 doi:10.3389/fnagi.2023.1229491.

Progressive supranuclear palsy: A case report and brief review of the literature.

Batheja V, Fish M, Balar AB, et al.

Radiology case reports 2024; (19(1)):250-253 doi:10.1016/j.radcr.2023.09.012.

Luxembourg Parkinson's study -comprehensive baseline analysis of Parkinson's disease and atypical parkinsonism.

Pavelka L, Rawal R, Ghosh S, et al.

Frontiers in neurology 2023; (14()):1330321 doi:10.3389/fneur.2023.1330321.

Phenotypic Spectrum of Progressive Supranuclear Palsy: Clinical Study and Apolipoprotein E Effect.

Nasri A, Sghaier I, Neji A, et al.

Journal of movement disorders 2024; (17(2)):158-170 doi:10.14802/jmd.23178.

[Neuropathology of the Neurodegenerative Diseases].

Iwasaki Y

Brain and nerve = Shinkei kenkyu no shinpo 2024; (76(4)):343-351 doi:10.11477/mf.1416202611.

Detecting Abnormal Eye Movements in Patients with Neurodegenerative Diseases - Current Insights.

Sekar A, Panouillères MTN, Kaski D

Eye and brain 2024; (16()):3-16 doi:10.2147/EB.S384769.

Frontal hypometabolism in the diagnosis of progressive supranuclear palsy clinical variants.

Black JA, Pham NTT, Ali F, et al.

Journal of neurology 2024; (271(7)):4267-4280 doi:10.1007/s00415-024-12350-z.

How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?

Lozupone M, Dibello V, Daniele A, et al.

Expert opinion on pharmacotherapy 2024; (25(5)):571-584 doi:10.1080/14656566.2024.2345734.

Histologic tau lesions and magnetic resonance imaging biomarkers differ across two progressive supranuclear palsy variants.

Orlandi F, Carlos AF, Ali F, et al.

Brain communications 2024; (6(2)):fcae113 doi:10.1093/braincomms/fcae113.

Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.

Dunning EE, Decourt B, Zawia NH, et al.

Neurology and therapy 2024; (13(4)):975-1013 doi:10.1007/s40120-024-00614-9.

Progressive supranuclear palsy, a case report.

Ortiz A, Troya F, de Vera J, Vázquez E

Archivos de la Sociedad Espanola de Oftalmologia 2024; (99(7)):304-308 doi:10.1016/j.oftale.2024.05.004.

Multidisciplinary care use in neurodegenerative complex diseases: The example of progressive supranuclear palsy and advanced Parkinson's disease in real-life.

Fabbri M, Ledda C, Schirinzi T, et al.

Parkinsonism & related disorders 2024; (125()):107047 doi:10.1016/j.parkreldis.2024.107047.

Astrocyte tau deposition in progressive supranuclear palsy is associated with dysregulation of MAPT transcription.

Jackson RJ, Melloni A, Fykstra DP, et al.

Acta neuropathologica communications 2024; (12(1)):132 doi:10.1186/s40478-024-01844-6.

MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.

Ressler HW, Humphrey J, Vialle RA, et al.

Acta neuropathologica communications 2024; (12(1)):135 doi:10.1186/s40478-024-01839-3.

Atypical Parkinsonian Syndromes: Structural, Functional, and Molecular Imaging Features.

Keir G, Roytman M, Mashriqi F, et al.

AJNR. American journal of neuroradiology 2024; (45(12)):1865-1877 doi:10.3174/ajnr.A8313.

Long-standing preservation of levodopa response in progressive supranuclear palsy.

Sano T, Mizutani M, Ishihara T, et al.

Journal of the neurological sciences 2024; (466()):123203 doi:10.1016/j.jns.2024.123203.

Acute Levodopa Challenge in Atypical Parkinsonism: Comprehensive Analysis of Individual Motor Responses.

Ye L, Sani SS, Veith Sanches L, et al.

Brain sciences 2024; (14(10)) doi:10.3390/brainsci14100991.

Pathological study of progressive supranuclear palsy the cases with mutations in Bassoon.

Wakita M, Yaguchi H, Otuski M, et al.

Neuropathology : official journal of the Japanese Society of Neuropathology 2025; (45(2)):140-152 doi:10.1111/neup.13009.

Quality of life in patients with progressive supranuclear palsy: a review of literature and implications for practice.

Markiewicz M, Madetko-Alster N, Alster P

Frontiers in neurology 2024; (15()):1476488 doi:10.3389/fneur.2024.1476488.

Progressive supranuclear palsy: an updated approach on diagnosis, treatment, risk factors and outlook in Mexico.

Gómez-Virgilio L, Gutiérrez-Malacara AI, Rivera-Osorio J, et al.

Gaceta medica de Mexico 2024; (160(4)):374-383 doi:10.24875/GMM.M24000930.

Clinical prognostic factors in progressive supranuclear palsy: Implications for clinical trials.

Marchand F, Blaise AS, Defebvre L, et al.

Journal of Parkinson's disease 2024; (14(8)):1652-1658 doi:10.1177/1877718X241291996.

I-Beam Sign in Progressive Supranuclear Palsy.

Manorenj S, Chillapuram S

Neurology India 2025; (73(2)):330-331 doi:10.4103/neurol-india.Neurol-India-D-24-00101.

Cell-specific mitochondrial response in progressive supranuclear palsy.

Sackmann V, Nassir N, Tanikawa S, et al.

Mitochondrion 2025; (84()):102043 doi:10.1016/j.mito.2025.102043.

Misdiagnosis of Frontotemporal Dementia in a Patient With Progressive Supranuclear Palsy: A Case Report and Volumetric Neuroimaging Application.

Eguiguren CB, Fabara MD, Diaz A

Cureus 2025; (17(3)):e81421 doi:10.7759/cureus.81421.

Magnetic Resonance Imaging in the Neuroimaging of Progressive Supranuclear Palsy-Parkinsonism Predominant: Limitations and Strengths in Clinical Evaluation.

Alster P, Kutyłowski M, Madetko-Alster N

Diagnostics (Basel, Switzerland) 2025; (15(8)) doi:10.3390/diagnostics15080945.

MAPT Subhaplotypes in Different Progressive Supranuclear Palsy Phenotypes.

Gagliardi M, Procopio R, Felicetti A, et al.

Biomedicines 2025; (13(6)) doi:10.3390/biomedicines13061405.

Progressive Supranuclear Palsy-A Global Review.

Kukkle PL, Neupane R, Pantelyat A, et al.

Movement disorders clinical practice 2025; doi:10.1002/mdc3.70338.

Understanding Tau pathology: Insights from animal models.

Zhang H, Pan MT, Li YX, et al.

Zoological research 2025; (46(5)):1244-1258 doi:10.24272/j.issn.2095-8137.2025.077.

Early subtypes and progressions of progressive supranuclear palsy: a data-driven brain bank study.

Ono D, Sekiya H, Ghayal NB, et al.

Journal of neurology 2025; (272(10)):704 doi:10.1007/s00415-025-13459-5.

Richardson Syndrome Variant of Progressive Supranuclear Palsy: A Case Report.

Korucu I, Karakoyun Alpay T

Cureus 2025; (17(12)):e98307 doi:10.7759/cureus.98307.

Inflammatory and Neurotrophic Factors and Their Connection to Quality of Life in Progressive Supranuclear Palsy-Single-Center Study.

Markiewicz M, Migda B, Otto-Ślusarczyk D, et al.

International journal of molecular sciences 2025; (26(24)) doi:10.3390/ijms262412122.